Free Trial

Moleculin Biotech (MBRX) Competitors

Moleculin Biotech logo
$0.54 -0.04 (-6.29%)
As of 03:56 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

MBRX vs. LPCN, CING, MTEX, GELS, CARM, MRKR, CTXR, RVPH, PMN, and GOVX

Should you be buying Moleculin Biotech stock or one of its competitors? The main competitors of Moleculin Biotech include Lipocine (LPCN), Cingulate (CING), Mannatech (MTEX), Gelteq (GELS), Carisma Therapeutics (CARM), Marker Therapeutics (MRKR), Citius Pharmaceuticals (CTXR), Reviva Pharmaceuticals (RVPH), Promis Neurosciences (PMN), and GeoVax Labs (GOVX). These companies are all part of the "pharmaceutical products" industry.

Moleculin Biotech vs. Its Competitors

Lipocine (NASDAQ:LPCN) and Moleculin Biotech (NASDAQ:MBRX) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, analyst recommendations, valuation, profitability, dividends, risk, media sentiment and institutional ownership.

9.1% of Lipocine shares are held by institutional investors. Comparatively, 15.5% of Moleculin Biotech shares are held by institutional investors. 6.4% of Lipocine shares are held by insiders. Comparatively, 1.9% of Moleculin Biotech shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Lipocine presently has a consensus price target of $9.00, indicating a potential upside of 175.23%. Moleculin Biotech has a consensus price target of $4.00, indicating a potential upside of 646.27%. Given Moleculin Biotech's higher possible upside, analysts clearly believe Moleculin Biotech is more favorable than Lipocine.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Lipocine
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
3.00
Moleculin Biotech
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
3.00

Lipocine's return on equity of -26.68% beat Moleculin Biotech's return on equity.

Company Net Margins Return on Equity Return on Assets
LipocineN/A -26.68% -24.77%
Moleculin Biotech N/A -278.80%-100.11%

In the previous week, Moleculin Biotech had 3 more articles in the media than Lipocine. MarketBeat recorded 4 mentions for Moleculin Biotech and 1 mentions for Lipocine. Moleculin Biotech's average media sentiment score of 0.56 beat Lipocine's score of 0.00 indicating that Moleculin Biotech is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Lipocine
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Moleculin Biotech
2 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Lipocine has higher revenue and earnings than Moleculin Biotech.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Lipocine$11.20M1.56$10K-$1.02-3.21
Moleculin BiotechN/AN/A-$21.76MN/AN/A

Lipocine has a beta of 1.3, meaning that its share price is 30% more volatile than the S&P 500. Comparatively, Moleculin Biotech has a beta of 1.38, meaning that its share price is 38% more volatile than the S&P 500.

Summary

Lipocine and Moleculin Biotech tied by winning 5 of the 10 factors compared between the two stocks.

Get Moleculin Biotech News Delivered to You Automatically

Sign up to receive the latest news and ratings for MBRX and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MBRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

MBRX vs. The Competition

MetricMoleculin BiotechMED IndustryMedical SectorNASDAQ Exchange
Market Cap$7.62M$2.97B$5.58B$9.03B
Dividend YieldN/A2.44%5.25%4.03%
P/E RatioN/A21.0427.1820.17
Price / SalesN/A258.76415.50184.26
Price / CashN/A41.8337.0657.97
Price / Book0.307.758.085.60
Net Income-$21.76M-$54.96M$3.16B$248.50M
7 Day Performance53.14%5.66%3.64%5.07%
1 Month Performance-19.03%4.10%3.78%7.53%
1 Year Performance-84.19%6.20%34.08%21.54%

Moleculin Biotech Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
MBRX
Moleculin Biotech
3.0837 of 5 stars
$0.54
-6.3%
$4.00
+646.3%
-82.4%$7.62MN/A0.0020News Coverage
Gap Down
LPCN
Lipocine
1.5854 of 5 stars
$3.16
-4.0%
$9.00
+184.8%
-58.4%$17.60M$11.20M-3.1010
CING
Cingulate
2.7282 of 5 stars
$4.07
+0.5%
$26.00
+538.8%
+1,116.8%$17.19MN/A-0.4820News Coverage
MTEX
Mannatech
0.2962 of 5 stars
$9.35
+3.9%
N/A+18.8%$17.11M$117.87M-93.50250High Trading Volume
GELS
Gelteq
N/A$1.73
-4.4%
N/AN/A$17.08M$100K0.00N/AGap Down
CARM
Carisma Therapeutics
2.4093 of 5 stars
$0.39
-2.2%
$1.93
+391.6%
-64.8%$16.74M$19.63M-0.2520Gap Down
MRKR
Marker Therapeutics
3.69 of 5 stars
$1.53
+4.8%
$13.17
+760.6%
-63.4%$16.52M$6.59M-1.1560
CTXR
Citius Pharmaceuticals
2.4542 of 5 stars
$1.59
+3.9%
$53.00
+3,233.3%
-89.5%$16.27MN/A0.0020Gap Down
High Trading Volume
RVPH
Reviva Pharmaceuticals
2.4579 of 5 stars
$0.38
+12.9%
$9.00
+2,261.6%
-67.5%$16.20MN/A-0.485Gap Up
High Trading Volume
PMN
Promis Neurosciences
3.3978 of 5 stars
$0.48
+0.7%
$4.50
+830.1%
-82.4%$15.70MN/A-9.685Gap Up
GOVX
GeoVax Labs
3.4136 of 5 stars
$0.87
-9.8%
$11.10
+1,182.2%
-74.1%$15.29M$3.95M-0.2410Analyst Revision

Related Companies and Tools


This page (NASDAQ:MBRX) was last updated on 7/10/2025 by MarketBeat.com Staff
From Our Partners